16 September 2022
Futura Medical plc
("Futura" or the "Company")
Exercise of Options, PDMR Dealing and Total Voting Rights
Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, announces that it has received notice to exercise options from James Barder, CEO, to exercise 500,000 options over ordinary shares of 0.2 pence in the Company ("Ordinary Shares").
James Barder has exercised options over 250,000 Ordinary Shares with an exercise price of 30 pence and options over 250,000 Ordinary Shares with an exercise price of 7.5 pence. In order to satisfy the exercise price of these options, 250,000 Ordinary Shares have been sold, with the remaining 250,000 Ordinary Shares retained. In addition, James and his spouse, Charlotte Barder have gifted 20,000 Ordinary Shares to a family member as part of inheritance and tax planning.
Following these transactions James Barder's interests in Ordinary Shares has increased to 1,440,972 Ordinary Shares, representing approximately 0.5% of the Company's issued share capital.
Total Voting Rights
Following the issue of 500,000 Ordinary Shares under the Company's existing block listings to satisfy the exercise of options, for the purposes of the FCA's Disclosure and Transparency Rules, the Company's total issued share capital at the date of this announcement is 287,650,971 Ordinary Shares.
Since the Company currently holds no shares in treasury, the total number of voting rights in the Company is 287,650,971 and this figure may therefore be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
-ENDS-
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
Nominated Adviser and Sole Broker:
Liberum
Phil Walker/ Richard Lindley/ Ben Cryer/ Kane Collings
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Hollie Vile/ Zoe Bolt
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 882 9621
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® technology. Each DermaSys® formulation is separately patented and specifically tailored for the selected indication and application, as well as being optimised for clinical efficacy, safety, administration and patient convenience. The products are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.
MED3000 is Futura's topical gel formulation that is a breakthrough treatment for erectile dysfunction ("ED") through a unique evaporative mode of action. Futura has previously conducted a Phase 3 study using MED3000 in ED, referred to as "FM57". This was a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study delivering highly statistically significant results compared to pre-treatment baseline, using measures IIEF-EF, SEP2 and SEP3 (internationally accepted clinical trial endpoints in ED) with over 60% of patients experiencing a clinically meaningful improvement in their ED.
MED3000 is CE marked in Europe and CA marked in the UK as a clinically proven topical treatment for adult men with erectile dysfunction under the brand Eroxon™ with a key claim of "Helps you get an erection within 10 minutes".
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) |
Name |
James Barder |
||||
|
2 |
Reason for the notification |
|||||
|
a) |
Position/status |
Chief Executive Officer |
||||
|
b) |
Initial notification /Amendment |
Initial notification |
||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Futura Medical plc |
||||
|
b) |
LEI |
21380053QLT46UNV2303 |
||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a)
|
Description of the financial instrument, type of instrument |
Ordinary Shares of 0.2 pence each |
||||
|
Identification code |
ISIN: GB0033278473 |
|||||
|
b) |
Nature of the transaction |
1. Exercise of options with exercise price of 30p 2. Disposal of ordinary shares following exercise 3. Exercise of options with exercise price of 7p 4. Gift of Ordinary shares |
||||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
1. |
£0.30 |
250,000 |
|
|
|
|
|
2. |
£0.452 |
250,000 |
|
|
|
|
|
3. |
£0.075 |
250,000 |
|
|
|
|
|
4. |
Nil |
20,000 |
|
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
||||
|
- Aggregated volume |
1. 250,000 2. 250,000 3. 250,000 4. 20,000
|
|||||
|
- Price |
1. £75,000 2. £113,000 3. £17,500 4. £nil |
|||||
|
e) |
Date of the transaction |
15 September 2022 |
||||
|
f) |
Place of the transaction |
1. Off market 2. XLON 3. Off market 4. Off market |
||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
